DK2044026T3 - Fremgangsmde til behandling af cerebral glioma tumor - Google Patents

Fremgangsmde til behandling af cerebral glioma tumor

Info

Publication number
DK2044026T3
DK2044026T3 DK07719115.3T DK07719115T DK2044026T3 DK 2044026 T3 DK2044026 T3 DK 2044026T3 DK 07719115 T DK07719115 T DK 07719115T DK 2044026 T3 DK2044026 T3 DK 2044026T3
Authority
DK
Denmark
Prior art keywords
procedures
treatment
glioma tumor
cerebral glioma
cerebral
Prior art date
Application number
DK07719115.3T
Other languages
Danish (da)
English (en)
Inventor
Jack Gordon Parsons
Vijaya Kenche
Penelope Jane Huggins
Gaik Beng Kok
Ashley Bush
Original Assignee
Prana Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prana Biotechnology Ltd filed Critical Prana Biotechnology Ltd
Application granted granted Critical
Publication of DK2044026T3 publication Critical patent/DK2044026T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
DK07719115.3T 2006-06-22 2007-06-22 Fremgangsmde til behandling af cerebral glioma tumor DK2044026T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81577906P 2006-06-22 2006-06-22
PCT/AU2007/000876 WO2007147217A1 (en) 2006-06-22 2007-06-22 Method of treatment of glioma brain tumour

Publications (1)

Publication Number Publication Date
DK2044026T3 true DK2044026T3 (da) 2014-06-30

Family

ID=38833006

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07719115.3T DK2044026T3 (da) 2006-06-22 2007-06-22 Fremgangsmde til behandling af cerebral glioma tumor

Country Status (9)

Country Link
US (1) US8163760B2 (OSRAM)
EP (1) EP2044026B1 (OSRAM)
JP (1) JP5415942B2 (OSRAM)
CN (1) CN101589026B (OSRAM)
AU (1) AU2007262670B2 (OSRAM)
CA (1) CA2656825C (OSRAM)
DK (1) DK2044026T3 (OSRAM)
ES (1) ES2474865T3 (OSRAM)
WO (1) WO2007147217A1 (OSRAM)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
EP2012789B1 (en) * 2006-04-14 2013-09-25 Prana Biotechnology Limited Method of treatment of age-related macular degeneration (AMD)
US8163779B2 (en) * 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US9493419B2 (en) 2007-08-21 2016-11-15 The Hong Kong Polytechnic University Quinoline derivatives as anti-cancer agents
US9321730B2 (en) * 2007-08-21 2016-04-26 The Hong Kong Polytechnic University Method of making and administering quinoline derivatives as anti-cancer agents
MY150596A (en) 2008-02-01 2014-01-30 Takeda Pharmaceutical Hsp90 inhibitors
GB0806794D0 (en) * 2008-04-15 2008-05-14 Ludwig Inst Cancer Res Therapeutic compounds
JP2011530596A (ja) * 2008-08-11 2011-12-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ ｔＲＮＡ合成酵素の阻害のためのハロフジノン類似体およびそれらの使用
JP5719779B2 (ja) * 2008-12-24 2015-05-20 プラナ バイオテクノロジー リミティッド キナゾリノン化合物
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2565186A1 (en) * 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
FR2984317B1 (fr) * 2011-12-20 2015-02-27 Univ Rennes Composes chelateurs de metal presentant au moins une chaine polyaminee.
US10155742B2 (en) 2012-01-13 2018-12-18 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
UA125503C2 (uk) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN104903300B (zh) * 2012-12-27 2018-04-17 霍夫曼-拉罗奇有限公司 Comt抑制剂
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
EP3061749B1 (en) * 2013-10-23 2019-02-27 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3227292B1 (en) * 2014-12-02 2022-03-09 Alterity Therapeutics Limited 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019067503A1 (en) * 2017-09-26 2019-04-04 Dana-Farber Cancer Institute, Inc. NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
EP3801525A4 (en) 2018-06-08 2022-03-23 The General Hospital Corporation PROLYL TRNA SYNTHETASE INHIBITORS
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
CN111471012B (zh) * 2019-01-23 2023-04-25 鲁南制药集团股份有限公司 一种蜈蚣喹啉类化合物、制备方法及其应用
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN110240590B (zh) * 2019-07-16 2025-09-19 广州新民培林医药科技有限公司 一类嘧啶喹啉衍生物及其制备方法和应用
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7765088B2 (ja) 2019-12-02 2025-11-06 ストーム・セラピューティクス・リミテッド Ｍｅｔｔｌ３阻害剤としてのポリヘテロ環式化合物
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
RS66978B1 (sr) 2020-07-02 2025-07-31 Incyte Corp Triciklična jedinjenja uree kao inhibitori jak2 v617f
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
WO2022182839A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
CN113214249B (zh) * 2021-04-23 2023-09-19 成都大学 吡啶并[1,2-a]嘧啶-4-硫酮化合物的合成方法
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20240144096A (ko) 2021-11-02 2024-10-02 플레어 테라퓨틱스 인크. Pparg 역 효능제 및 그의 용도
KR20240163688A (ko) 2022-03-17 2024-11-19 인사이트 코포레이션 Jak2 v617f 억제제로서의 삼환계 우레아 화합물
CN116410132B (zh) * 2023-02-23 2024-07-09 广东工业大学 一种8-羟基喹啉类化合物及其制备方法和在制备抗肿瘤药物上的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524620A (ja) 1999-03-24 2003-08-19 アノーメッド インコーポレイティド ケモカインレセプター結合複素環化合物
DE60128655T2 (de) * 2000-01-24 2008-02-07 Astrazeneca Ab Durch einen morpholinrest substituierte therapeutische verbindungen
AU2002230056A1 (en) 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Indole derivatives and their uses as heparanase inhibitors
AU2002313633B2 (en) 2001-06-08 2007-03-01 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
CA2475773A1 (en) * 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
CA2500727A1 (en) 2002-10-03 2004-04-15 Targegen, Inc. Vasculostatic agents and methods of use thereof
NZ539211A (en) * 2002-10-04 2008-05-30 Prana Biotechnology Ltd Neurologically-active compounds
WO2005063213A1 (en) * 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
US20060100226A1 (en) 2004-09-10 2006-05-11 Sikorski James A 2-Thiopyrimidinones as therapeutic agents
NZ568666A (en) * 2005-11-30 2011-09-30 Vertex Pharma [1,2,4]Triazolo[3,4-b][1,3,4]thiadiazole derivative as inhibitors of c-Met
DE102005059479A1 (de) * 2005-12-13 2007-06-14 Merck Patent Gmbh Hydroxychinolinderivate
EP2012789B1 (en) * 2006-04-14 2013-09-25 Prana Biotechnology Limited Method of treatment of age-related macular degeneration (AMD)

Also Published As

Publication number Publication date
US8163760B2 (en) 2012-04-24
WO2007147217A1 (en) 2007-12-27
CA2656825A1 (en) 2007-12-27
AU2007262670A2 (en) 2009-03-26
JP5415942B2 (ja) 2014-02-12
CA2656825C (en) 2013-12-10
JP2009541223A (ja) 2009-11-26
ES2474865T3 (es) 2014-07-09
EP2044026A1 (en) 2009-04-08
AU2007262670B2 (en) 2012-12-20
EP2044026B1 (en) 2014-03-26
EP2044026A4 (en) 2009-08-05
CN101589026B (zh) 2013-10-16
US20100069393A1 (en) 2010-03-18
AU2007262670A1 (en) 2007-12-27
CN101589026A (zh) 2009-11-25

Similar Documents

Publication Publication Date Title
DK2044026T3 (da) Fremgangsmde til behandling af cerebral glioma tumor
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
CR10679A (es) Novel anti-cd38 antibodies for the treatment of cancer
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
SI2391650T1 (sl) Postopki za zdravljenje protina
DK3401334T5 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
DK2019683T4 (da) Indgivelse af vækstfaktorer til behandling af CNS-lidelser
BRPI0821779A2 (pt) tratamento terapêutico de câncer
DK2440230T3 (da) Behandlingsregimener til behandling af neurologisk sygdom
DK2162149T3 (da) Vaccine til forebyggelse af brystkræfttilbagefald
DK2452189T3 (da) Fremgangsmåde til identifikation af forbindelser til behandling af cancer
DK2209784T3 (da) Forbindelser til behandling af hepatitis C
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme